journal
MENU ▼
Read by QxMD icon Read
search

Breast Cancer Research and Treatment

journal
https://www.readbyqxmd.com/read/28933052/erratum-to-utilization-of-bioimpedance-spectroscopy-in-the-prevention-of-chronic-breast-cancer-related-lymphedema
#1
David I Kaufman, Chirag Shah, Frank A Vicini, Marisa Rizzi
In the original publication of the article, under the heading, Study limitations in the Discussion section, the second paragraph, fifth sentence was published incorrectly as "Patients with an L-Dex increase of ≥ 5.5 undergo…sleeve for 4 weeks".
September 20, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28929449/concordance-analysis-of-paired-cancer-antigen-ca-15-3-and-27-29-testing
#2
David C Lin, Jonathan R Genzen
PURPOSE: Cancer antigens (CA) 15-3 and 27.29 are used in the clinical management of many breast cancer patients. Given that immunoassays for CA 15-3 and CA 27.29 target epitopes on the same glycoprotein-Mucin 1 (MUC1)-the present analysis was conducted to evaluate the potential concordance of tumor marker results when both tests were ordered by providers on the same specimens. METHODS: A retrospective limited dataset of paired CA 15-3 (Roche Diagnostics) and CA 27...
September 19, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28929359/immunohistochemical-versus-molecular-blueprint-and-mammaprint-subtyping-of-breast-carcinoma-outcome-results-from-the-eortc-10041-big-3-04-mindact-trial
#3
G Viale, F A de Snoo, L Slaets, J Bogaerts, L van 't Veer, E J Rutgers, M J Piccart-Gebhart, L Stork-Sloots, A Glas, L Russo, P Dell'Orto, K Tryfonidis, S Litière, F Cardoso
PURPOSE: This study compares immunohistochemical (IHC) versus molecular subtyping (BluePrint and MammaPrint) in the population of patients enrolled in MINDACT and outcome based on molecular subtyping (MS) versus surrogate pathological subtyping (PS) as defined by the 2013 St. Gallen guidelines. METHODS: MS classified patients in the following subtypes: Luminal A, Luminal B, HER-2-, and Basal-type. IHC/FISH for pathological subtyping (ER, PgR, HER-2, and Ki67) was centrally assessed in the European Institute of Oncology (n = 5806)...
September 19, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28921303/registry-study-to-assess-hair-loss-prevention-with-the-penguin-cold-cap-in-breast-cancer-patients-receiving-chemotherapy
#4
Brooke A Rice, Elizabeth S Ver Hoeve, Amy N DeLuca, Laura J Esserman, Hope S Rugo, Michelle E Melisko
PURPOSE: Chemotherapy-induced alopecia is a distressing side effect of cancer treatment. The aim of this registry study was to assess efficacy and tolerability of scalp hypothermia using Penguin Cold Caps (Penguin) in breast cancer patients. METHODS: Hair loss was assessed by patients using a 100-point Visual Analog Scale (VAS) and by physicians using the 5-point Dean Scale at baseline, every 3-4 weeks during chemotherapy, and at least 1 month after completion of chemotherapy...
September 18, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28918548/tumor-and-serum-dna-methylation-in-women-receiving-preoperative-chemotherapy-with-or-without-vorinostat-in-tbcrc008
#5
Roisin M Connolly, Mary Jo Fackler, Zhe Zhang, Xian C Zhou, Matthew P Goetz, Judy C Boughey, Bridget Walsh, John T Carpenter, Anna Maria Storniolo, Stanley P Watkins, Edward W Gabrielson, Vered Stearns, Saraswati Sukumar
BACKGROUND: Methylated gene markers have shown promise in predicting breast cancer outcomes and treatment response. We evaluated whether baseline and changes in tissue and serum methylation levels would predict pathological complete response (pCR) in patients with HER2-negative early breast cancer undergoing preoperative chemotherapy. METHODS: The TBCRC008 trial investigated pCR following 12 weeks of preoperative carboplatin and albumin-bound paclitaxel + vorinostat/placebo (n = 62)...
September 16, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28918479/rebuttal-comments
#6
LETTER
Daniel B Kopans
No abstract text is available yet for this article.
September 16, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28914398/characteristics-and-prognosis-of-breast-cancer-after-liver-or-kidney-transplantation
#7
I-Ji Jeong, Sung-Gyu Lee, Young Hoon Kim, Beom Seok Ko, Jong Won Lee, Byung Ho Son, Se-Hyun Ahn, Hee Jeong Kim
PURPOSE: Immunoediting is crucial in cancer development and progression. This study compared the characteristics and prognosis of post-transplant breast cancer (PTBC) patients receiving immunosuppressants and general breast cancer patients. METHODS: Data from the Asan Medical Center Breast Cancer (AMCBC), kidney transplantation, and liver transplantation databases recorded during 1989-2013 were retrospectively analyzed. Four controls of AMCBC cohort per one case of PTBC cohort were selected based on tumor size, lymph node metastasis, and age...
September 15, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28914396/the-expected-benefit-of-preventive-mastectomy-on-breast-cancer-incidence-and-mortality-in-brca-mutation-carriers-by-age-at-mastectomy
#8
Vasily Giannakeas, Steven A Narod
PURPOSE: Preventive breast surgery is offered to unaffected BRCA mutation carriers to prevent breast cancer incidence and mortality. The clinical benefit of preventive mastectomy can be measured in several ways, including extension of life expectancy (mean years of life gained) and by estimating the probability of surviving until age 80. We sought to estimate the expected benefit of a preventive mastectomy at various ages, using these indices of mortality, by simulating hypothetical cohorts of women...
September 15, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28913760/impact-of-histopathology-tumor-infiltrating-lymphocytes-and-adjuvant-chemotherapy-on-prognosis-of-triple-negative-breast-cancer
#9
Roberto A Leon-Ferre, Mei-Yin Polley, Heshan Liu, Judith A Gilbert, Victoria Cafourek, David W Hillman, Ahmed Elkhanany, Margaret Akinhanmi, Jenna Lilyquist, Abigail Thomas, Vivian Negron, Judy C Boughey, Minetta C Liu, James N Ingle, Krishna R Kalari, Fergus J Couch, Daniel W Visscher, Matthew P Goetz
BACKGROUND: Given its high recurrence risk, guidelines recommend systemic therapy for most patients with early-stage triple-negative breast cancer (TNBC). While some clinicopathologic factors and tumor-infiltrating lymphocytes (TILs) are known to be prognostic in patients receiving chemotherapy, their prognostic implications in systemically untreated patients remain unknown. METHODS: From a cohort of 9982 women with surgically treated non-metastatic breast cancer, all patients with clinically reported ER-negative/borderline (≤10%) disease were selected for central assessment of ER/PR/HER2, histopathology, Ki-67, and TILs...
September 14, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28913734/molecular-profile-of-atypical-hyperplasia-of-the-breast
#10
REVIEW
David N Danforth
PURPOSE: Atypical ductal and atypical lobular hyperplasia (AH) of the breast are important proliferative lesions which are associated with a significantly increased risk for breast cancer. The breast cancer which develops in association with AH may occur synchronously, representing local progression, or metachronously at a later date in either the ipsilateral or contralateral breast. These high-risk characteristics of AH suggest they contain significant genomic changes. METHODS: To define the genomic changes in AH, a comprehensive review of the literature was conducted to identify the numerical chromosomal and structural chromosomal changes, DNA methylation, and gene expression abnormalities in atypical ductal and atypical lobular hyperplasia...
September 14, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28913729/exome-array-analysis-identifies-etfb-as-a-novel-susceptibility-gene-for-anthracycline-induced-cardiotoxicity-in-cancer-patients
#11
Sara Ruiz-Pinto, Guillermo Pita, Miguel Martín, Teresa Alonso-Gordoa, Daniel R Barnes, María R Alonso, Belén Herraez, Purificación García-Miguel, Javier Alonso, Antonio Pérez-Martínez, Antonio J Cartón, Federico Gutiérrez-Larraya, José A García-Sáenz, Javier Benítez, Douglas F Easton, Ana Patiño-García, Anna González-Neira
PURPOSE: Anthracyclines are widely used chemotherapeutic drugs that can cause progressive and irreversible cardiac damage and fatal heart failure. Several genetic variants associated with anthracycline-induced cardiotoxicity (AIC) have been identified, but they explain only a small proportion of the interindividual differences in AIC susceptibility. METHODS: In this study, we evaluated the association of low-frequency variants with risk of chronic AIC using the Illumina HumanExome BeadChip array in a discovery cohort of 61 anthracycline-treated breast cancer patients with replication in a second independent cohort of 83 anthracycline-treated pediatric cancer patients, using gene-based tests (SKAT-O)...
September 14, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28913660/weight-gain-in-hormone-receptor-positive-hr-early-stage-breast-cancer-is-it-menopausal-status-or-something-else
#12
Kirsten A Nyrop, Allison M Deal, Jordan T Lee, Hyman B Muss, Seul Ki Choi, Amy Wheless, Lisa A Carey, Shlomit S Shachar
PURPOSE: This study investigates weight trajectories in pre- versus postmenopausal breast cancer (BC) survivors diagnosed with hormone receptor-positive tumors, with a specific focus on discerning menopausal status and type of endocrine treatment (ET) as risk factors for weight gain during ET. METHODS: We conducted a retrospective review of electronic medical records. Descriptive statistics and Chi-squared and t tests were used to compare pre- and postmenopausal women...
September 14, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28913650/does-levonorgestrel-releasing-intrauterine-system-increase-breast-cancer-risk-in-peri-menopausal-women-an-hmo-perspective
#13
Nava Siegelmann-Danieli, Itzhak Katzir, Janet Vesterman Landes, Yaakov Segal, Rachel Bachar, Hadas Rotem Rabinovich, Martin Bialik, Joseph Azuri, Avi Porath, Yossef Lomnicky
PURPOSE: To evaluate the association between levonorgestrel-releasing intrauterine system (LNG-IUS) use and breast cancer (BC) risk. METHODS: A cohort of all Maccabi Healthcare Services (MHS) female members aged 40-50 years between 1/2003 and 12/2013 was used to identify LNG-IUS users as "cases," and 2 age-matched non-users as "controls." Exclusion criteria included: prior BC diagnosis, prior (5 years pre-study) and subsequent treatment with other female hormones or prophylactic tamoxifen...
September 14, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28905250/tumour-infiltrating-lymphocytes-tils-related-genomic-signature-predicts-chemotherapy-response-in-breast-cancer
#14
Mariko Kochi, Takayuki Iwamoto, Naoki Niikura, Giampaolo Bianchini, Shinobu Masuda, Taeko Mizoo, Tomohiro Nogami, Tadahiko Shien, Takayuki Motoki, Naruto Taira, Yutaka Tokuda, Hiroyoshi Doihara, Junji Matsuoka, Toshiyoshi Fujiwara
PURPOSE: The present study evaluated whether morphological-measured stromal and intra-tumour tumour-infiltrating lymphocytes (TILs) levels were associated with gene expression profiles, and whether TILs-associated genomic signature (GS) could be used to predict clinical outcomes and response to therapies in several breast cancer subtypes. METHODS: We retrospectively evaluated haematoxylin eosin (HE)-TILs levels and gene expression profiling data from 40 patients with primary breast cancer and extracted the 22 overexpressed genes in cases with high TILs scores as the TILs-GS...
September 13, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28905136/highly-sensitive-detection-of-esr1-mutations-in-cell-free-dna-from-patients-with-metastatic-breast-cancer-using-molecular-barcode-sequencing
#15
Nanae Masunaga, Naofumi Kagara, Daisuke Motooka, Shota Nakamura, Tomohiro Miyake, Tomonori Tanei, Yasuto Naoi, Masafumi Shimoda, Kenzo Shimazu, Seung Jin Kim, Shinzaburo Noguchi
PURPOSE: We aimed to develop a highly sensitive method to detect ESR1 mutations in cell-free DNA (cfDNA) using next-generation sequencing with molecular barcode (MB-NGS) targeting the hotspot segment (c.1600-1713). METHODS: The sensitivity of MB-NGS was tested using serially diluted ESR1 mutant DNA and then cfDNA samples from 34 patients with metastatic breast cancer were analyzed with MB-NGS. The results of MB-NGS were validated in comparison with conventional NGS and droplet digital PCR (ddPCR)...
September 13, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28900788/take-care-of-your-neighborhood
#16
Elmer E Huerta, Patricia Weeks-Coulthurst, Courtney Williams, Sandra M Swain
PURPOSE: Urban women in certain Washington, DC neighborhoods present with advanced breast cancer at high rates despite access to health insurance and health care. METHODS: Through a two-phase intervention, community health workers (CHWs) educated and surveyed individuals regarding healthcare utilization and breast health and cancer awareness. In phase I, CHWs educated and administered a survey to 1092 women, of whom 95.1% had health insurance, in an attempt to explain the high rate of advanced breast cancer despite having health insurance...
September 12, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28900752/healthcare-utilization-medicare-spending-and-sources-of-patient-distress-identified-during-implementation-of-a-lay-navigation-program-for-older-patients-with-breast-cancer
#17
Gabrielle B Rocque, Courtney P Williams, Meredith I Jones, Kelly M Kenzik, Grant R Williams, Andres Azuero, Bradford E Jackson, Karina I Halilova, Karen Meneses, Richard A Taylor, Ed Partridge, Maria Pisu, Elizabeth A Kvale
PURPOSE: Despite benefits for patients, sustainability of breast cancer navigation programs is challenging due to the lack of reimbursement for navigators. This analysis describes distress reported by breast cancer patients to navigators and the impact of navigation on healthcare utilization for older adults with breast cancer. METHODS: We conducted a retrospective cohort study of Medicare administrative claims data and patient-reported distress assessments. The primary outcome was Medicare spending per beneficiary per quarter...
September 12, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28900739/a-frameshift-mutation-in-brca1-leads-to-hereditary-breast-and-ovarian-cancer-in-one-part-of-a-family-and-to-familial-pancreatic-cancer-in-another
#18
LETTER
Laura Gieldon, Johannes Wagner, Andreas Rump
No abstract text is available yet for this article.
September 12, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28895005/durable-complete-response-in-her2-positive-breast-cancer-a-multicenter-retrospective-analysis
#19
Naoki Niikura, Akihiko Shimomura, Yumi Fukatsu, Masataka Sawaki, Rin Ogiya, Hiroyuki Yasojima, Tomomi Fujisawa, Mitsugu Yamamoto, Michiko Tsuneizumi, Akira Kitani, Junichiro Watanabe, Akira Matsui, Yuko Takahashi, Seiki Takashima, Tadatoshi Shien, Kenji Tamura, Shigehira Saji, Norikazu Masuda, Yutaka Tokuda, Hhiroji Iwata
PURPOSE: Though advanced and metastatic epidermal growth factor receptor 2 (HER2)-positive disease is not curable, a small proportion of patients with HER2-positive metastatic breast cancer remain in prolonged complete remission with anti-HER2 treatment. We hypothesized that some cases of HER2-positive metastatic breast cancer may be curable. In this large, multicenter retrospective study, we aimed to assess the long-term outcomes for patients with a durable response to trastuzumab. METHODS: We retrospectively evaluated the data of patients diagnosed with HER2-positive metastatic breast cancer who received trastuzumab for more than 2 years as the first-line treatment...
September 11, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28894982/severe-depression-more-common-in-patients-with-ductal-carcinoma-in-situ-than-early-stage-invasive-breast-cancer-patients
#20
M L Gregorowitsch, H J G D van den Bongard, D A Young-Afat, J P Pignol, C H van Gils, A M May, H M Verkooijen
PURPOSE: Ductal carcinoma in situ (DCIS) is associated with an excellent prognosis; historical studies have shown similar levels of psychological distress in patients with DCIS and with early-stage invasive breast cancer (early-IBC). It is suggested that these results might have led to better patient education about prognosis after DCIS. This study reports the current levels of anxiety, depression, and health-related quality of life (HRQoL) in DCIS and early-IBC patients. METHODS: DCIS (n = 89) and early-IBC patients, T1-2N0, (n = 361) were selected from the UMBRELLA breast cancer cohort...
September 11, 2017: Breast Cancer Research and Treatment
journal
journal
28253
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"